Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Impact Of Rebates On Drug Pricing Will Diminish -- CMS Experts

Executive Summary

Actuaries with the US Centers for Medicare and Medicaid Services predict the share of retail prescription drug costs represented by manufacturer rebates will level off in the coming years, resulting in higher drug pricing trends across government and commercial insurance.

Related Content

Medicare Part D Spending Projected To Decline in 2018 As Rebates Increase
US Retail Drug Spending Growth Slows Substantially In 2016
Medicare May Require Part D Plans To Provide Point-of-Sale Rebates





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts